Loading clinical trials...
Loading clinical trials...
The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Cedars Sinai Medical Center
Los Angeles, California, United States
University Of Chicago
Chicago, Illinois, United States
The Bunting Blaustein Cancer Research Building
Baltimore, Maryland, United States
Memorial Sloan-Kettering Cancer Center-Sidney Kimmel Center
New York, New York, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr
Madison, Wisconsin, United States
Local Institution
Montpellier, France
Local Institution
Paris, France
Local Institution
Villejuif, France
Start Date
January 1, 2007
Primary Completion Date
December 1, 2008
Completion Date
October 1, 2010
Last Updated
April 30, 2013
94
ACTUAL participants
dasatinib
DRUG
dasatinib
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT04550494
NCT05691465
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions